ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Test Drug 1-1 (GBP511 low dose)

A development code. Also written as “Test Drug 1-2 (GBP511 mid dose)”, “Test Drug 1-3 (GBP511 high dose)” and “Test Drug 2-1 (GBP511 low dose + CAS-1)”.

Its studies are led by SK Chemicals.

Furthest: phase 2, since Nov 26, 20251 company-led study, 1 open or runningNext primary completion: Dec 9, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
SK Chemicals11 open or runningphase 2since Nov 26, 2025Nov 26, 2025Dec 9, 2026phase 2 · NCT07280858

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 26, 2025First study: phase 2 study in Healthy ParticipantsFirst studyNCT07280858 · 368 enrolled · Australia

Ahead

  1. Dec 9, 2026Primary completion: phase 2 study in Healthy ParticipantsNCT07280858

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07280858Healthy Participants · Australia2Active, not recruitingDec 9, 2026368

How it is read

Names in the registry

  • “Test Drug 1-1 (GBP511 low dose)”, 1 entry
  • “Test Drug 1-2 (GBP511 mid dose)”, 1 entry
  • “Test Drug 1-3 (GBP511 high dose)”, 1 entry
  • “Test Drug 2-1 (GBP511 low dose + CAS-1)”, 1 entry
  • “Test Drug 2-2 (GBP511 mid dose + CAS-1)”, 1 entry

Codes read as this program: GBP511.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.